Peer-reviewed research work

Please refer to Pubmed for the most current list of our publications.
Selected publications
  1. Liang J, Gondane A, Itkonen HM*. CDK12-inactivation-induced MYC signaling causes dependency on the splicing kinase SRPK1. Molecular Oncology.PMID: 38775167.
  2. Yalala S, Gondane  A, Poulose N, Liang J, Mills IG, Itkonen HM*. CDK9 inhibition activates innate immune response through viral mimicry. FASEB Journal. PMID: 38661032. 
  3. Gondane A, Girmay S, Helevä A, Pallasaho S, Loda M, Itkonen HM*. O-GlcNAc transferase couples MRE11 to transcriptionally active chromatin to suppress DNA damage. Journal of Biomedical Science 2022. PMID: 35164752.
  4. Itkonen HM, Minner S, Guldvik IJ, Sandmann MJ, Tsourlakis MC, Berge V, Svindland A, Schlomm T, Mills IG*. O-GlcNAc transferase integrates metabolic pathways to regulate the stability of c-MYC in human prostate cancer cells. Cancer Research 2013. PMID: 23720054.
2024
  1. Israel JS, Marcelin LM, Thomas C, Szczyrbová E, Fuessel S, Puhr M, Linxweiler J, Yalala S, Zwart WT, Baniahmad A, van Goubergen J, Itkonen HM, Sharp A, O'Neill E, Pretze M, Miederer M, Erb HHH. Emerging frontiers in androgen receptor research for prostate Cancer: insights from the 2nd international androgen receptor Symposium. J Exp Clin Cancer Res.  PMID: 39014480. 
  2. Yalala S, Gondane  A, Poulose N, Liang J, Mills IG, Itkonen HM*. CDK9 inhibition activates innate immune response through viral mimicry. FASEB Journal. PMID: 38661032. 
  3. Liang J, Gondane A, Itkonen HM*. CDK12-inactivation-induced MYC signaling causes dependency on the splicing kinase SRPK1. Molecular Oncology.PMID: 38775167.
2023

1. Gondane A* and Itkonen HM*. Revealing the History and Mystery of RNA-Seq. Curr. Issues Mol. Biol. 2023. PMID: 36975490. 
2022
  1. Pallasaho S, Gondane A, Kuivalainen A, Girmay S, Moestue S, Loda M, Itkonen HM*. Castration-resistant prostate cancer cells are dependent on the high activity of CDK7. Journal of Cancer Research and Clinical Oncology 2022. PMID: 36401094.
  2. Gondane A, Poulose N, Walker S, Mills IG, Itkonen HM*. O-GlcNAc transferase maintains metabolic homeostasis in response to CDK9 inhibition. Glycobiology 2022. PMID: 35708495.
  3. Gondane A, Girmay S, Helevä A, Pallasaho S, Loda M, Itkonen HM*. O-GlcNAc transferase couples MRE11 to transcriptionally active chromatin to suppress DNA damage. Journal of Biomedical Science 2022. PMID: 35164752.
2021
  1. Pallasaho S, Gondane A, Duveau D, Thomas C, Loda M, Itkonen HM*. Compromised CDK12 activity causes dependency on the non-essential spliceosome components. bioRxiv 2021; DOI: 10.1101/2021.12.07.470703.
  2. Itkonen HM*, Loda M, Mills IG*. O-GlcNAc Transferase - An Auxiliary Factor or a Full-blown Oncogene? Molecular Cancer Research 2021. PMID: 33472950.
  3. Hu Q, Poulose N, Girmay S, Helevä A, Doultsinos D, Gondane A, Steele RE, Liu X, Loda M, Liu S, Tang DG, Mills IG, Itkonen HM*. Inhibition of CDK9 activity compromises global splicing in prostate cancer cells. RNA Biology 2021. PMID: 34592899.
2020
  1. Barkovskaya A, Seip K, Prasmickaite L, Mills IG, Moestue SA, Itkonen HM*. Inhibition of O-GlcNAc transferase activates tumor-suppressor gene expression in tamoxifen-resistant breast cancer cells. Scientific Reports 2020. PMID: 33046784.
  2. Itkonen HM*, Poulose N, Steele RE, Martin SES, Levine ZG, Duveau DY, Carelli R, Singh R, Urbanucci A, Loda M, Thomas CJ, Mills IG*, Walker S*. Inhibition of O-GlcNAc Transferase Renders Prostate Cancer Cells Dependent on CDK9. Molecular Cancer Research 2020. PMID: 32611550.
2019
  1. Itkonen HM*, Poulose N, Walker S*, Mills IG*. CDK9 Inhibition Induces a Metabolic Switch that Renders Prostate Cancer Cells Dependent on Fatty Acid Oxidation. Neoplasia 2019. PMID: 31151054.
  2. Itkonen HM*, Urbanucci A, Martin SE, Khan A, Mathelier A, Thiede B, Walker S*, Mills IG*. High OGT activity is essential for MYC-driven proliferation of prostate cancer cells. Theranostics 2019. PMID: 31149037.
  3. Barkovskaya A, Seip K, Hilmarsdottir B, Maelandsmo GM, Moestue SA, Itkonen HM*. O-GlcNAc Transferase Inhibition Differentially Affects Breast Cancer Subtypes. Scientific Reports 2019. PMID: 30952976.
2018
  1. Martin SES, Tan ZW, Itkonen HM, Duveau DY, Paulo JA, Janetzko J, Boutz PL, Törk L, Moss FA, Thomas CJ, Gygi SP, Lazarus MB, Walker S*. Structure-Based Evolution of Low Nanomolar O-GlcNAc Transferase Inhibitors. Journal of the American Chemical Society. 2018. PMID: 30285435.
2017
  1. Fan Q, Nørgaard RC, Bindesbøll C, Lucas C, Dalen KT, Babaie E, Itkonen HM, Matthews J, Nebb HI, Grønning-Wang LM*. LXRα Regulates Hepatic ChREBPα Activity and Lipogenesis upon Glucose, but Not Fructose Feeding in Mice. Nutrients 2017. PMID: 28661453.
  2. Urbanucci A*, Barfeld SJ, Kytölä V, Itkonen HM, Coleman IM, Vodák D, Sjöblom L, Sheng X, Tolonen T, Minner S, Burdelski C, Kivinummi KK, Kohvakka A, Kregel S, Takhar M, Alshalalfa M, Davicioni E, Erho N, Lloyd P, Karnes RJ, Ross AE, Schaeffer EM, Vander Griend DJ, Knapp S, Corey E, Feng FY, Nelson PS, Saatcioglu F, Knudsen KE, Tammela TLJ, Sauter G, Schlomm T, Nykter M, Visakorpi T, Mills IG*. Androgen Receptor Deregulation Drives Bromodomain-Mediated Chromatin Alterations in Prostate Cancer. Cell Reports 2017. PMID: 28591577.
  3. Itkonen HM*, Brown M, Urbanucci A, Tredwell G, Ho Lau C, Barfeld S, Hart C, Guldvik IJ, Takhar M, Heemers HV, Erho N, Bloch K, Davicioni E, Derua R, Waelkens E, Mohler JL, Clarke N, Swinnen JV, Keun HC, Rekvig OP, Mills IG*. Lipid degradation promotes prostate cancer cell survival. Oncotarget 2017. PMID: 28415728.
  4. Barfeld SJ, Urbanucci A, Itkonen HM, Fazli L, Hicks JL, Thiede B, Rennie PS, Yegnasubramanian S, DeMarzo AM, Mills IG*. c-Myc Antagonises the Transcriptional Activity of the Androgen Receptor in Prostate Cancer Affecting Key Gene Networks. EBioMedicine 2017. PMID: 28412251.
2016
  1. Itkonen HM*, Kantelinen J, Vaara M, Parkkinen S, Schlott B, Grosse F, Nyström M, Syväoja JE, Pospiech H*. Human DNA polymerase α interacts with mismatch repair proteins MSH2 and MSH6. FEBS Letters 2016. PMID: 27805738.
  2. Itkonen HM*, Gorad SS, Duveau DY, Martin SE, Barkovskaya A, Bathen TF, Moestue SA, Mills IG. Inhibition of O-GlcNAc transferase activity reprograms prostate cancer cell metabolism. Oncotarget 2016. PMID: 26824323.
2015
  1. Itkonen HM*, Engedal N, Babaie E, Luhr M, Guldvik IJ, Minner S, Hohloch J, Tsourlakis MC, Schlomm T, Mills IG*. UAP1 is overexpressed in prostate cancer and is protective against inhibitors of N-linked glycosylation. Oncogene 2015. PMID: 25241896.
  2. Itkonen HM*, Mills IG. Studying N-linked glycosylation of receptor tyrosine kinases. Methods Molecular Biology 2015. PMID: 25319893.
2014
  1. Barfeld SJ, Itkonen HM, Urbanucci A, Mills IG. Androgen-regulated metabolism and biosynthesis in prostate cancer. Endocrine Related Cancer 2014. PMID: 24497572.
2013
  1. Itkonen HM, Mills IG*. N-linked glycosylation supports cross-talk between receptor tyrosine kinases and androgen receptor. PLoS One 2013. PMID: 23724116.
  2. Itkonen HM, Minner S, Guldvik IJ, Sandmann MJ, Tsourlakis MC, Berge V, Svindland A, Schlomm T, Mills IG*. O-GlcNAc transferase integrates metabolic pathways to regulate the stability of c-MYC in human prostate cancer cells. Cancer Research 2013. PMID: 23720054.
2012
  1. Paulo P, Ribeiro FR, Santos J, Mesquita D, Almeida M, Barros-Silva JD, Itkonen H, Henrique R, Jerónimo C, Sveen A, Mills IG, Skotheim RI, Lothe RA, Teixeira MR*. Molecular subtyping of primary prostate cancer reveals specific and shared target genes of different ETS rearrangements. Neoplasia 2012. PMID: 22904677.
  2. Vaara M, Itkonen H, Hillukkala T, Liu Z, Nasheuer HP, Schaarschmidt D, Pospiech H, Syväoja JE* Segregation of replicative DNA polymerases during S phase: DNA polymerase ε, but not DNA polymerases α/δ, are associated with lamins throughout S phase in human cells. Journal of Biological Chemistry 2012. PMID: 22887995.
  3. Itkonen H*, Mills IG*. Chromatin binding by the androgen receptor in prostate cancer. Molecular and Cellular Endocrinology 2012. PMID: 21989426.